Exploring potential biomarkers and lead molecules in gastric cancer by network biology, drug repurposing and virtual screening strategies
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-10995-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Sagarika Saha und 3 weiteren Autor:innen. Beteiligte Einrichtung: MIT ADTU School of Bioengineering Sciences & Research, MIT Art, Design and Technology University, Pune, Maharashtra, India. Hauptthemen laut MEDLINE: Stomach Neoplasms, Drug Repositioning, Biomarkers, Tumor, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 99 Literaturangaben.
Abstract (Originalsprache)
Gastric cancer poses a significant global health challenge, necessitating innovative approaches for biomarker discovery and therapeutic intervention. This study employs a multifaceted strategy integrating network biology, drug repurposing, and virtual screening to elucidate and expand the molecular landscape of gastric cancer. We identified and prioritized key genes implicated in gastric cancer by utilizing data from diverse databases and text-mining techniques. Network analysis underscored intricate gene interactions, emphasizing potential therapeutic targets such as CTNNB1, BCL2, TP53, etc, and highlighted ACTB among the top hub genes crucial in disease progression. Drug repurposing on 626 FDA-approved drugs for digestive system-related cancers revealed Norgestimate and Nimesulide as likely top candidates for gastric cancer, validated by molecular docking and dynamics simulations. Further, combinatorial synthesis of scaffold libraries derived from known chemotypes generated 56,160 virtual compounds, of which 76 new compounds were prioritized based on promising binding affinities and interactions at critical residues. Hotspot residue analysis identified GLU 214 and others as essential for ligand binding stability, enhancing compound efficacy and specificity. These findings support the therapeutic potential of targeting beta-actin protein in gastric cancer treatment, suggesting a future for further experimental validation and clinical translation. In conclusion, this study highlights the potential of repurposable drugs and virtual screening which can be used in combination with existing anti-gastric cancer drugs for gastric cancer therapy, emphasizing the role of computational methodologies in drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MIT ADTU School of Bioengineering Sciences & Research, MIT Art, Design and Technology University, Pune, Maharashtra, India.
- MIT ADTU School of Bioengineering Sciences & Research, MIT Art, Design and Technology University, Pune, Maharashtra, India. renu.vyas@mituniversity.edu.in.
Zitieren
APA
Saha, S., Bapat, S., Vijayasarathi, D., & Vyas, R. (2025). Exploring potential biomarkers and lead molecules in gastric cancer by network biology, drug repurposing and virtual screening strategies. Molecular Diversity. https://doi.org/10.1007/s11030-024-10995-6
Vancouver
Saha S, Bapat S, Vijayasarathi D, Vyas R. Exploring potential biomarkers and lead molecules in gastric cancer by network biology, drug repurposing and virtual screening strategies. Molecular Diversity. 2025. doi:10.1007/s11030-024-10995-6
BibTeX
@article{Saha2025,
author = {Saha, Sagarika and Bapat, Sanket and Vijayasarathi, Durairaj and Vyas, Renu},
title = {Exploring potential biomarkers and lead molecules in gastric cancer by network biology, drug repurposing and virtual screening strategies},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-10995-6}
}
EUVIMED